Darshan G,
Hamsa Priya M,
Bharath B,
- Student, Department of Pharmacy, Aditya Bangalore Institute of Pharmacy Education and Research, Bangalore, Karnataka, India
- Student, Department of Pharmacy, Aditya Bangalore Institute of Pharmacy Education and Research, Bangalore, Karnataka, India
- Student, Department of Pharmacy, Aditya Bangalore Institute of Pharmacy Education and Research, Bangalore, Karnataka, India
Abstract
For the treatment of obesity and type 2 diabetes mellitus (T2DM), glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have become a revolutionary class of pharmaceutical drugs. These drugs were first created as glucose-lowering treatments, but they have now shown other advantages, such as notable weight loss, better cardiovascular results, and general metabolic control. The objective of this narrative review is to assess the pharmacological mechanisms, clinical efficacy, safety profile, and therapeutic implications of GLP-1 receptor agonists, with a focus on their dual role in the management of obesity and diabetes. Randomized controlled trials, meta-analyses, and clinical guidelines published between 2010 and 2025 were all included in the extensive literature search that was carried out utilizing electronic databases like PubMed, Scopus, and Web of Science. There is evidence that GLP-1 RAs lead to sustained weight loss via improving glycemic control through glucose-dependent insulin secretion, delayed stomach emptying, and increased satiety. Moreover, significant clinical trials have shown decreases in mortality and cardiovascular events. These drugs are usually well tolerated, despite the frequent occurrence of moderate gastrointestinal side effects. In conclusion, GLP-1 receptor agonists offer a comprehensive strategy for successfully controlling type 2 diabetes and obesity and constitute a paradigm change in the treatment of metabolic illnesses.
Keywords: GLP-1 receptor agonists; Type 2 diabetes mellitus; Obesity; Semaglutide; Liraglutide; Pharmacotherapy; Clinical pharmacy
[This article belongs to Research and Reviews: A Journal of Pharmacology ]
Darshan G, Hamsa Priya M, Bharath B. GLP-1 Receptor Agonists: A Dual Therapeutic Strategy for the Management of Type 2 Diabetes Mellitus and Obesity. Research and Reviews: A Journal of Pharmacology. 2026; 16(01):-.
Darshan G, Hamsa Priya M, Bharath B. GLP-1 Receptor Agonists: A Dual Therapeutic Strategy for the Management of Type 2 Diabetes Mellitus and Obesity. Research and Reviews: A Journal of Pharmacology. 2026; 16(01):-. Available from: https://journals.stmjournals.com/rrjop/article=2026/view=239732
References
1. Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27(4):740–56.
2. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–22.
3. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–44.
4. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002.
5. Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND). Lancet. 2019;394(10193):121–30.
6. Davies MJ, Bergenstal R, Bode B, et al. Efficacy of liraglutide for weight loss. N Engl J Med. 2015;373(1):11–22.
7. Nauck MA, Meier JJ. Incretin hormones: Their role in health and disease. Diabetes Obes Metab. 2018;20(S1):5–21.
8. American Diabetes Association. Standards of medical care in diabetes—2024. Diabetes Care. 2024;47(Suppl 1):S1–S350.
9. Rubino DM, Greenway FL, Khalid U, et al. Effect of weekly semaglutide vs placebo on weight loss. JAMA. 2021;325(14):1414–25.
10. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132(6):2131–57.
11. Pratley R, Amod A, Hoff ST, et al. Oral semaglutide versus placebo. Diabetes Care. 2019;42(9):1724–32.
12. Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in diabetes. Lancet. 2021;398(10296):726–40.
13. Kushner RF, Calanna S, Davies M, et al. Semaglutide 2.4 mg for obesity. Diabetes Obes Metab. 2020;22(12):2132–41.
14. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin cardiovascular outcomes. N Engl J Med. 2015;373(22):2117–28.
15. Frias JP, Nauck MA, Van J, et al. Tirzepatide versus semaglutide. N Engl J Med. 2021;385(6):503–15.
Research and Reviews: A Journal of Pharmacology
| Volume | 16 |
| Issue | 01 |
| Received | 22/03/2026 |
| Accepted | 02/04/2026 |
| Published | 05/04/2026 |
| Publication Time | 14 Days |
Login
PlumX Metrics